Science (02/17/95) Vol. 267, No. 5200, P. 966
An advisory panel to the Food and Drug Administration (FDA)
recently decided that although the vaccine made by the Immune
Response Corporation (IRC) holds limited promise, it is safe
enough to use in a three-year study involving more than 3,002
participants. The vaccine--the brainchild of Jonas Salk, the
developer of the polio vaccine--is a whole, killed version of
HIV minus its surface protein. The IRC scientists and
researchers told the panel how the vaccine had boosted the
immune system and decreased HIV levels of patients in small-
scale studies. Many panel members, however, were skeptical.
"My instincts tell me it will not show efficacy," said
virologist Stanley Lemon of the University of North Carolina.
The committee finally approved the trial because the vaccine
does not appear to produce serious side effects.